Neutrophil migration is defective during recombinant human granulocyte-
macrophage colony-stimulating factor infusion after autologous bone marrow
transplantation in humans
WP Peters, A Stuart, ML Affronti, CS Kim and RE Coleman
Department of Medicine, Duke University Medical Center, Durham, NC 27710.
We have previously reported that continuous intravenous (IV) administration
of recombinant granulocyte-macrophage colony-stimulating factor (rHuGM-CSF)
to humans following high-dose alkylating agent chemotherapy and autologous
bone marrow support (ABMS) results in myeloid bone marrow maturation,
accelerated granulocyte recovery, and reduced treatment-related toxicity.
However, we found that leukocyte counts declined rapidly after
discontinuation of rHuGM-CSF therapy, which suggests possible growth factor
effects on leukocyte margination and migration. For these reasons we
studied granulocyte margination by using 111In-labeled autologous
granulocytes and found similar granulocyte margination before (21.5% +/-
13.4%) and during continuous IV rHuGM-CSF infusion (23.3% +/- 9.6%).
Phagocytosis of Cryptococcus neoformans and granulocyte hydrogen peroxide
production was similar before and during rHuGM-CSF infusion and similar to
patients treated with the same high-dose chemotherapy and ABMS but not
receiving growth factor. However, migration of granulocytes to a sterile
inflammatory site was markedly reduced during continuous rHuGM-CSF infusion
(1.2 +/- 0.9 WBCs/cm2, 24 hr) as compared with baseline (39.6 +/- 17.7
WBCs/cm2/24 hr; P less than .0008). These findings may be of relevance when
extravascular granulocytes are required for host defense.
Volume 72,
Issue 4,
pp. 1310-1315,
10/01/1988
Copyright © 1988 by The American Society of Hematology
